List View

By /

Clear

Displaying 1,276 - 1,300 of 2,995

Novel Advances in H&N and Thyroid Cancers

Novel Advances in H&N and Thyroid Cancers

Management of Melanoma: Early and Advanced Stages

Management of Melanoma: Early and Advanced Stages

Neurological Complications and Management in the Era of Checkpoint Inhibitors

Neurological Complications and Management in the Era of Checkpoint Inhibitors

Colorectal Cancer: Chemotherapy Combinations Targeted Therapy and Immunotherapy

Colorectal Cancer: Chemotherapy Combinations Targeted Therapy and Immunotherapy

Pancreas and Biliary Carcinomas: Novel Advances

Pancreas and Biliary Carcinomas: Novel Advances

Prostate Cancer: From Hormonal Manipulation to Targeted Therapy

Prostate Cancer: From Hormonal Manipulation to Targeted Therapy

Favoring The Neoadjuvant Concept

Favoring The Neoadjuvant Concept

Favoring The Adjuvant Concept

Favoring The Adjuvant Concept

Stage IIIA-B-C NSCLC: Does The PACIFIC Data Fit All-in-One?

Stage IIIA-B-C NSCLC: Does The PACIFIC Data Fit All-in-One?

What After Immunotherapy Failure in First Line: Is There Hope?

What After Immunotherapy Failure in First Line: Is There Hope?

Management of EGFR Mutant NSCLC Patients and Future Directions (excluding Resistance to EGFR TKIs)

Management of EGFR Mutant NSCLC Patients and Future Directions (excluding Resistance to EGFR TKIs)

EGFR PKI Resistance and K-RAS Mutations

EGFR PKI Resistance and K-RAS Mutations

ALK & ROS-1: First Line & Mechanism of Resistance

ALK & ROS-1: First Line & Mechanism of Resistance

Novel Targets: HER-2, NRG1, TROP2, CEACAM5 & HER-3

Novel Targets: HER-2, NRG1, TROP2, CEACAM5 & HER-3

Cost of Medications: How to Make Them Affordable—Are We on the Right Direction?

Cost of Medications: How to Make Them Affordable—Are We on the Right Direction?

Are The New Changes in Congress an Answer for Inequity in Terms of Access to Molecular Testing and New Cancer Agents?

Are The New Changes in Congress an Answer for Inequity in Terms of Access to Molecular Testing and New Cancer Agents?

Oncology Payments Models: Where Are We Going?

Oncology Payments Models: Where Are We Going?

Novel Platforms to Assess the Cancer Continuom Using Liquid Biopsy

Novel Platforms to Assess the Cancer Continuom Using Liquid Biopsy

Bispecific Antibodies in Cancer Care: Actual Reality and Future Projections

Bispecific Antibodies in Cancer Care: Actual Reality and Future Projections

Novel Advances in Radiation Oncology Beyond SRS and Proton Therapy: What Is Next?

Novel Advances in Radiation Oncology Beyond SRS and Proton Therapy: What Is Next?

Novel Advances in the Therapy of Kidney and Bladder Carcinomas

Novel Advances in the Therapy of Kidney and Bladder Carcinomas

Ovarian-Uterine & Fallopian Tube Carcinomas

Ovarian-Uterine & Fallopian Tube Carcinomas

New Developments in Sarcoma Therapy

New Developments in Sarcoma Therapy

Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

DLBCL & Hodgkin’s Disease

DLBCL & Hodgkin’s Disease